Our study also found that treatment with CV1 in combination with CDH17-CAR-NK92 led to an increase in CD69+ and CD86+ macrophages, potently implicating the enhanced antitumor activity of tumor-associated macrophages. The gene discussed is CD86; the disease is neoplasm.